Follow The Filings

CERS Cerus Corporation

Health Care, filed as Cerus Corp (COMMON STOCK), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.3%
  • $52M
  • 1 reduce

In 2026 Q2 Cathie Wood trimmed Cerus.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Cathie Wood, Ark Investment Management). Not free-float ownership.

  1. Cathie Wood Reduce 0.34%

Who owns CERS

Sorted by value, long equity only, as of 2026 Q2.

History
Cathie Wood, Ark Investment Management 0.34% Reduce −6.4% 17,932,099 $52M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CERS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CERS insider trades
  • None no insider bought on the open market
  • $53K sold by 1 insider outside a trading plan
  • $652K sold by 4 insiders under 10b5-1 plans
  1. Chrystal Jensen Chief Legal Officer
    Planned sale
    $90K 30,000 shares at $2.98 3.1% of stake
    Traded Aug 17 Filed Aug 17
    ↗
  2. Vivek K Jayaraman CEO
    Planned sale
    $53K 16,666 shares at $3.16 0.7% of stake
    Traded Jul 16 Filed Jul 20
    ↗
  3. Eric Bjerkholt Director
    Sale
    $53K 20,454 shares at $2.60 7.2% of stake
    Traded Jun 9 Filed Jun 11
    ↗
  4. Vivek K Jayaraman COO
    Planned sale
    $50K 16,667 shares at $3.00 1% of stake
    Traded May 29 Filed Jun 2
    ↗
  5. Vivek K Jayaraman COO
    Planned sale
    $50K 16,667 shares at $3.00 1% of stake
    Traded May 1 Filed May 5
    ↗
  6. Richard J Benjamin Chief Medical Officer
    Planned sale
    $202K 101,659 shares at $1.99 10% of stake
    Traded Mar 5–9 Filed Mar 10
    ↗
  7. Kevin Dennis Green CFO
    Planned sale
    $114K 55,225 shares at $2.06 4.4% of stake
    Traded Mar 5 Filed Mar 9
    ↗
  8. Chrystal Jensen Chief Legal Officer
    Planned sale
    $94K 55,000 shares at $1.70 7% of stake
    Traded Nov 24, 2025 Filed Nov 26, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 23 stock grants and 13 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02 Filing Doc
8-K 1.01,1.02,2.03 Filing Doc
8-K 5.02,5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 12 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $186.8M $201.32M $233.8M
Net income -$37.49M -$20.92M -$15.63M
Net margin * -20.1% -10.4% -6.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $144.44M $152.02M $174.38M
Total non-current assets * $53.31M $48.9M $47.48M
Total assets $197.75M $200.92M $221.86M
Total current liabilities $67.52M $63.61M $100.8M
Total non-current liabilities * $76.78M $80.41M $56.09M
Total equity $52.65M $56.14M $64.22M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$43.17M $11.36M $4.84M
Cash from investing $8.62M -$8.13M -$6.16M
Cash from financing $10.67M $4.96M $0.231M
Net change in cash -$24M $8M -$0.761M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.